More than 20 CEOs from some of the biggest companies in Indiana sent a letter to top Republican lawmakers Wednesday urging them to restore a list of victim characteristics in bias-crimes legislation being considered by the Indiana General Assembly.
The Indianapolis-based drugmaker is facing calls by a national animal-rights group to end the “forced swim test” in small animals. Two months ago, drugmaker AbbVie said it would drop the test.
Indiana is currently one of a few states without a hate crimes law and getting off that list is important to the state’s economic development and talent-recruitment efforts.
A partnership forged six years ago to match disabled college students with paid internships has blossomed into the Eskenazi Health Initiative for Empowerment and Economic Independence.
The Senate amended Senate Bill 12 so it no longer specifies that crimes motivated by bias based on race, religion, sexual orientation, gender identity and other categories are eligible for stronger penalties.
After more than three hours of testimony and discussion on Monday morning, the Senate Public Policy Committee voted to send the bill to the full Senate for consideration.
The suit accuses the companies of raising insulin sticker prices by more than 150 percent over five years, forcing diabetics to forgo the drug, take less insulin than needed or use expired versions
For a startup that has raised an eye-popping $71 million in just three years, Outpost Medicine LLC likes to keep a low profile. The young company, which is developing drugs for urinary and gastrointestinal disorders, is headquartered in small, unmarked space at the Parkwood Crossing office complex on East 96th Street. It has issued only a […]
Call it “A Tale of Two (Troubled) Deals”—the struggles facing Amazon’s HQ2 project in New York and the uncertain future of the massive Foxconn manufacturing facility in southeastern Wisconsin, both of which are nightmarish for elected officials and economic developers. The local interest in Amazon is obvious; it’s hard not to greet stories of NYC […]
Greenfield-based Elanco spun off from Lilly last fall after 53 years. The former parent company still owns 80.2 percent of Elanco stock but has announced a program to unload it.
When the Indianapolis-based drug giant made its initial offer Dec. 20, it said it wanted to seal the deal before the J.P. Morgan Healthcare Conference, which ran Jan. 7-10 in San Francisco.
The Indianapolis-based pharmaceutical giant on Wednesday tempered expectations for its earnings in 2019 after a promising cancer drug failed to pan out and the firm prepared for big acquisition.
The Indianapolis drugmaker said the drug, baricitinib, proved effective in treating adults with a severe form of eczema. It’s the latest turn for a drug that has had repeated setbacks.
The Trump administration Thursday unveiled a plan to channel now-hidden prescription drug rebates directly to patients, saying it would bypass middlemen and lower prices for consumers.
The soaring Hispanic population can be a powerful engine for growth in the Indiana economy—potential that some of the state’s best-known businesses are embracing.
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
Sen. Ron Wyden, the ranking Democrat on the committee, singled out Humalog, an insulin made by Indianapolis-based Eli Lilly and Co, as a drug with unwarranted price hikes.
Lartruvo shouldn’t be started in new patients, and those patients already taking it should ask their doctors if they should continue, U.S. regulators said, following a key study that failed to show the medicine prolonged lives.
Jose Evans has decided to not to run for mayor and has thrown his support behind State Sen. Jim Merritt. And City-County Council member Jefferson Shreve, who replaced Jeff Miller last year, won’t seek a return to the council after his current term ends.
